MedTrace Logo

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-12-29

No results posted yet for this study

Summary

This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.

Conditions

  • Healthy

Interventions

DRUG

ALXN2050

ALXN2050 will be administered orally twice daily as powder-in-capsule.

DRUG

ALXN2050-matching Placebo

ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.

DRUG

Moxifloxacin

Moxifloxacin will be administered as a single oral dose.

DRUG

Moxifloxacin-matching Placebo

Moxifloxacin-matching placebo will be administered as a single oral dose.

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-12
Primary Completion
2021-03-16
Completion
2021-03-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04660890 on ClinicalTrials.gov